Team

Pablo Menéndez

Founder and CSO

Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology and childhood leukemia. He returned to Granada as Director of The Andalusian Stem Cell Bank and Principal Investigator at GENyO, a Pfizer-Andalusian Health Department centre for Genomics and Oncology (2007-2013). Since July 2013 he is an ICREA Research Professor and he heads the "Stem cell biology, developmental leukemia and Immunotherapy" group at the Josep Carreras Leukemia Institute-Campus Clinic Hospital-School of Medicine of the University of Barcelona. Pablo Menendez has published 190 peer-review publications with an accumulated impact factor of 1600 (H and i10 factors are 54 and 140, respectively). His work has been cited 10500 times. He has obtained solid competitive national and international research funding, has filed 10 patents in stem cell biology and immunotherapy, and has supervised >30 scientific staff including master, PhD students, postdoctoral scientists and technicians.

Jorge Alemany

CEO

Jorge has a long experience in research and management in prestigious institutions such as the NIH in the USA or at the Nactional Cancer Center (CNIO) in Spain. He has work in PharmaGen (today Genómica SAU.), Genetrix and Spherium Biomed. Founder of Cellerix, later Tigenix, that was acquired by Takeda Pharmaceuticals in 2018. Cellerix developed the first Cell Therapy product approved by the EMA.

Wilmar Castillo Ávila

Project Manager

Wilmar has more than 15 years of biomedical research experience at the University of Barcelona, the pharmaceutical company Ferrer and the Catalan Institute of Oncology. During the last 6 years, she has focused her work on managing pharmaceutical development projects in different therapeutic areas in companies such as AlbaJuna Therapeutics SL and Spherium Biomed SL. As a project manager, she has led and coordinated multifunctional teams to ensure preclinical and clinical projects' progress.

Víctor M. Díaz Cortés

Research Director

With more than 15 years in biomedical and oncological research at the Autonomous University of Barcelona, the Hospital de la Vall d'Hebron, the New York University School of Medicine and the San Raffaele Biomedical Science Park in Milan, and the IMIM-Hospital del Mar. After completing his postdoctoral training, he joined the Universitat Pompeu Fabra as a full professor and later as an assistant, and has recently joined the International University of Catalonia.

Laura García Pérez

Scientist

Biologist graduated at the University of Granada, she did her PhD in Immunology at the section of Molecular Gastroenterology and Immunology of the University Medical Center Hamburg-Eppendorf and the Immunobiology department at Yale University. Her research has focused on the role of T-cell derived cytokines in the context of intestinal inflammation and carcinogenesis. After her first postdoctoral training at the University Medical Center Hamburg-Eppendorf, she is joining OneChain Immunetherapeutics as Scientist